CClinicalTrials.gg
TerminatedNCT03447639Updated Jan 18, 2020Results posted

Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal

A Phase 4 interventional study of Povidone-iodine irrigation in Catheter; Infection (Indwelling Catheter), Catheter Infection and Catheter-Related Infections, sponsored by William Beaumont Hospitals. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by William Beaumont Hospitals · Phase 4, Interventional, and Prevention

Why this study was terminated
Lack of Patient Enrollment
Phase
Phase 4
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Over the last decade, there has been great emphasis on reducing the incidence of hospital-acquired infections, including catheter-associated UTI (CAUTI). This study will evaluate the effectiveness of Betadine irrigation solution (2% povidone-iodine) instilled into the bladder immediately prior to indwelling catheter removal to decrease the risk of subsequent bacteriuria, leading to decreased rates of NHSN defined CAUTI.

Read the detailed description

Indwelling urinary catheters are routinely used in the care of hospitalized patients for a variety of reasons, including monitoring of urine output in critically ill patients, relief of urinary obstruction, and prevention of contamination of decubitus ulcers. Bacteriuria increases by 3-10% each day a catheter is left in place, meaning that by 30 days, generally 100% of patients with indwelling catheters will have bacteria in their urine. The majority of these people do not have urinary tract infections (UTIs), they are merely colonized and do not require treatment.

To define a standard (and ultimately to compare hospitals against each other), a surveillance definition for CAUTI has been developed by the National Healthcare Safety Network (NHSN). While useful for surveillance, the definition does not correlate with clinical UTIs, leading to over diagnosis and over-reporting of UTIs (in other words, those with merely bladder colonization being diagnosed as having a UTI). Despite continuing progress in standard methods of reducing infection rates (including decreasing the number of catheters inserted, ensuring proper catheter maintenance, and removing catheters when no long necessary) there continue to be unacceptably high rates of CAUTIs.

A single dose of povidone-iodine prior to catheter removal seems a novel and promising practice for several reasons. First, we suspect it will be helpful in reducing rates of NHSN defined CAUTI, as these are still diagnosed for 2 days after the catheter is removed. Second, using multiple doses of povidone-iodine would be inadvisable, since we suspect bacteria over time would become resistant even to this antiseptic. Third, we suspect use of an antiseptic is preferable to an antibacterial for preventing further antimicrobial resistance development. Finally, use of this method, as opposed to the suggested use of systemic antibiotics at time of removal, is potentially preferable from the downstream standpoint of less antimicrobial resistance and reduced risk of Clostridium difficile infection.

02

Conditions studied

  • Catheter; Infection (Indwelling Catheter)
  • Catheter Infection
  • Catheter-Related Infections
  • Catheter Bacteraemia
  • Urinary Tract Infections

Keywords

  • Catheter associated UTI
  • Povidine iodine
  • Bladder Irrigation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  1. Provide written informed consent and the willingness and ability to comply with all aspects of study requirements
  2. Male
  3. Inpatients ≥ 18 years of age with an indwelling catheter in place for at least 5 days with a plan for removal

Exclusion criteria

Exclusion Criteria:

  1. Patients planned for discharge with an indwelling catheter in place
  2. Patients unable to report urinary symptoms accurately
  3. Patients with hyper-sensitivity or allergic reaction to Betadine, iodine, shellfish or other related compounds
  4. Clinical signs or symptoms of urinary tract infection at the time of consent
  5. Patients currently being treated for UTI
  6. Patients currently taking any antibiotic medication, other than vancomycin, linezolid, daptomycin, clindamycin, or metronidazole.
  7. Patients already taking medications known to potentially irritate the bladder, such as, but not limited to, cyclophosphamide, ifosfamide, and other chemotherapeutic agents
  8. Patients with history of bladder cancer, pelvic radiation or interstitial cystitis
  9. Patients unable to comply with study requirements
  10. Any other condition which, per investigators' judgment, may increase patient risk and/or impede the reliability of study data
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Povidone-Iodine Irrigation

    Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal

    Drug: Povidone-iodine irrigation

  • No intervention
    Standard of Care

    Catheter removal with no bladder irrigation

Interventions

  • DrugPovidone-iodine irrigation

    Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique

    Also known as: Betadine

05

What researchers measure

Primary outcomes

  1. Diagnosis of Urinary Tract Infection (UTI)

    Per NHSN defined catheter associated UTI (CAUTI) criteria

    Time frame: 48-72 hours after catheter removal

Secondary outcomes

  1. Diagnosis of UTI at 7 Days

    Per National Healthcare Safety Network (NHSN) defined CAUTI criteria

    Time frame: 7 days after catheter removal

  2. Diagnosis of UTI at 28 Days

    Per NHSN defined CAUTI criteria

    Time frame: 28 days after catheter removal

06

Results

Posted Apr 24, 2019

Participant flow

Patients were recruited from the inpatient units of the hospital.

Participant flow — Overall Study
MilestonePovidone-Iodine IrrigationStandard of Care
Started03
Completed01
Not completed02

Outcome measures

PrimaryDiagnosis of Urinary Tract Infection (UTI)

Per NHSN defined catheter associated UTI (CAUTI) criteria

Time frame:
48-72 hours after catheter removal

No measurements were reported for this outcome.

SecondaryDiagnosis of UTI at 7 Days

Per National Healthcare Safety Network (NHSN) defined CAUTI criteria

Time frame:
7 days after catheter removal

No measurements were reported for this outcome.

SecondaryDiagnosis of UTI at 28 Days

Per NHSN defined CAUTI criteria

Time frame:
28 days after catheter removal

No measurements were reported for this outcome.

Adverse events

Collected over 28 days; from study enrollment through the study completion. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Povidone-Iodine Irrigation———
Standard of Care0/3 (0%)0/3 (0%)0/3 (0%)

Baseline characteristics

No patients were randomized to the Povidone-Iodine arm

Age, Categorical
Age, Categorical(Participants)Povidone-Iodine IrrigationStandard of CareTotal
<=18 years000
Between 18 and 65 years033
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Povidone-Iodine IrrigationStandard of CareTotal
Female000
Male033
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Povidone-Iodine IrrigationStandard of CareTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Povidone-Iodine IrrigationStandard of CareTotal
United States033
Presence of urinary tract infection
Presence of urinary tract infection(Participants)Povidone-Iodine IrrigationStandard of CareTotal
Count of participants000
07

Study locations

1 site
  • Beaumont Hospital
    Royal Oak, Michigan 48073, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Oct 25, 2018
  • Informed consent form · Aug 2, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03447639
Lead sponsor
William Beaumont Hospitals
Responsible party
Jay Hollander MD (Attending Urologist, William Beaumont Hospitals) — Principal investigator
First posted
Feb 27, 2018
Start date
Mar 29, 2018
Primary completion
Oct 18, 2018
Completion
Oct 22, 2018
Results posted
Apr 24, 2019
Last update
Jan 18, 2020

Study contacts

Jay Hollander, MD
principal investigator · William Beaumont Hospitals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion